Tue, Feb 25, 9:10 PM (19 days ago)
Nuvectis Pharma, Inc. (NVCT) is a clinical-stage biopharma focused on developing precision oncology therapeutics, with two lead candidates, NXP800 and NXP900. In 2024, the company reported operating expenses of approximately $19.8M—a reduction from 2023—with R&D expenses at $12.9M and G&A at $6.9M. The firm remains pre-revenue with net losses of $19M and an accumulated deficit exceeding $73M, supported by $18.5M in cash as of December 31, 2024. Its strategy emphasizes advancing clinical trials, managing capital through IPOs, private placements, and ATM offerings, while facing risks from regulatory uncertainties, dependence on third-party manufacturers, and intellectual property challenges.